ID   KATO III Ola-R
AC   CVCL_C1ND
SY   KATO-III/olaparib-resistant; Olaparib-resistant KATO-III
DR   Wikidata; Q114311804
RX   PubMed=32028591;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:83766; Olaparib.
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C2993; Down syndrome
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
DI   ORDO; Orphanet_870; Down syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0371 ! KATO III
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 29-06-23; Version: 4
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//